Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I F Gazi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical and Experimental Rheumatology|April 10, 2007
Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statinsI F Gazi, D T Boumpas, D P Mikhailidis, et al.
Current Pharmaceutical Design|December 16, 2006
Statins and solid organ transplantationI F Gazi, E N Liberopoulos, V G Athyros, et al.
Journal of Lipid Research|June 19, 2009
Persistence of an atherogenic lipid profile after treatment of acute infection with BrucellaF Apostolou, I F Gazi, A Kostoula, et al.
Atherosclerosis|July 3, 2010
Acute infection with Epstein-Barr virus is associated with atherogenic lipid changesF Apostolou, I F Gazi, K Lagos, et al.
European Journal of Clinical Investigation|January 5, 2008
Increased plasma visfatin levels in subjects with the metabolic syndromeT D Filippatos, C S Derdemezis, I F Gazi, et al.
Atherosclerosis|August 17, 2006
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndromeT D Filippatos, I F Gazi, E N Liberopoulos, et al.
Lipids|October 29, 2008
Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndromeK G Lagos, T D Filippatos, V Tsimihodimos, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|October 4, 2011
Increased plasma visfatin concentration is a marker of an atherogenic metabolic profileT D Filippatos, V Tsimihodimos, C S Derdemezis, et al.
Diabetes, Obesity & Metabolism|April 27, 2007
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndromeT D Filippatos, E N Liberopoulos, M Kostapanos, et al.
International Journal of Clinical Practice|September 20, 2007
Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular diseaseG E Vrentzos, J A Papadakis, E S Ganotakis, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical and Experimental Rheumatology|April 10, 2007
Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statinsI F Gazi, D T Boumpas, D P Mikhailidis, et al.
Current Pharmaceutical Design|December 16, 2006
Statins and solid organ transplantationI F Gazi, E N Liberopoulos, V G Athyros, et al.
Journal of Lipid Research|June 19, 2009
Persistence of an atherogenic lipid profile after treatment of acute infection with BrucellaF Apostolou, I F Gazi, A Kostoula, et al.
Atherosclerosis|July 3, 2010
Acute infection with Epstein-Barr virus is associated with atherogenic lipid changesF Apostolou, I F Gazi, K Lagos, et al.
European Journal of Clinical Investigation|January 5, 2008
Increased plasma visfatin levels in subjects with the metabolic syndromeT D Filippatos, C S Derdemezis, I F Gazi, et al.
Atherosclerosis|August 17, 2006
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndromeT D Filippatos, I F Gazi, E N Liberopoulos, et al.
Lipids|October 29, 2008
Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndromeK G Lagos, T D Filippatos, V Tsimihodimos, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|October 4, 2011
Increased plasma visfatin concentration is a marker of an atherogenic metabolic profileT D Filippatos, V Tsimihodimos, C S Derdemezis, et al.
Diabetes, Obesity & Metabolism|April 27, 2007
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndromeT D Filippatos, E N Liberopoulos, M Kostapanos, et al.
International Journal of Clinical Practice|September 20, 2007
Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular diseaseG E Vrentzos, J A Papadakis, E S Ganotakis, et al.
Pageof 1